Abbott Laboratories (ABT) Stock Analysis
Verdict: HOLD
MedTech expansion and Exact Sciences integration drive long-term upside, but legal settlements and insider selling weigh on momentum.
Investment score: 61/100
Analysis as of
Is Abbott Laboratories stock worth reviewing? AI model thesis
The model score of 61/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment.
7-factor investment score
- Valuation: 68/100 (weight 20%)
- Financial Health: 75/100 (weight 15%)
- Technical Momentum: 48/100 (weight 15%)
- Earnings Quality: 52/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 78/100 (weight 10%)
- Risk-Adjusted Return: 70/100 (weight 15%)
Abbott Laboratories opportunities and risks
What speaks for ABT
- Continuous Glucose Monitoring (CGM) and AI Expansion
What speaks against ABT
- Infant Formula Legal Settlement Cash Outflows
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| ABT | 32.5x | 3.7x | 20.3x | 56.8% | 11.6% | 5.0% |
| ISRG | 46.6x | 13.2x | 31.7x | 66.7% | 28.4% | 2.2% |
| SYK | 28.7x | 4.1x | 18.9x | 65.2% | 14.4% | 4.4% |
| BSX | 17.7x | 3.1x | 13.6x | 71.2% | 17.5% | 5.6% |
| EW | 50.6x | 7.8x | 31.5x | 78.0% | 15.4% | 2.8% |
| BDX | 54.8x | 2.4x | 17.0x | 46.1% | 4.5% | 5.2% |
| Peer median | 46.6x | 4.1x | 18.9x | 66.7% | 15.4% | 4.4% |
Frequently asked questions about Abbott Laboratories (ABT)
Is ABT stock a good investment?
The cached TradeMates AI model rates Abbott Laboratories as HOLD with an investment score of 61/100. The model score of 61/100 falls in the HOLD range. The central thesis and factor breakdown explain the assessment. This is algorithmic model output, not personal investment advice.
Is ABT stock a buy?
The TradeMates model verdict for ABT is HOLD with an investment score of 61/100. Treat this as a model signal to review, not a personal buy recommendation.